NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. Receive News & Ratings for Intellia Therapeutics Daily - Enter your ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

Ronald Palacios Castrillo ¿Las terapias de edición genética realmente ayudan a los pacientes? Aunque ha habido un considerable entusiasmo sobre la perspectiva de administrar directamente una terapia d ...

SteelPeak Wealth LLC lessened its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 15.7% during the fourth quarter, according to its most recent disclosure with the ...

Cuál es el símbolo bursátil de Intellia Therapeutics Inc? El símbolo bursátil de Intellia Therapeutics Inc es “NTLA”. ¿Cuál es la capitalización de mercado de Intellia Therapeutics Inc?

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: February 4 at 6:46:43 PM EST Loading Chart for NTLA ...